GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » EV-to-EBIT

RVXCF (Resverlogix) EV-to-EBIT : -2.45 (As of Dec. 11, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Resverlogix EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Resverlogix's Enterprise Value is $20.78 Mil. Resverlogix's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-8.50 Mil. Therefore, Resverlogix's EV-to-EBIT for today is -2.45.

The historical rank and industry rank for Resverlogix's EV-to-EBIT or its related term are showing as below:

RVXCF' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.5   Med: 0   Max: 67.31
Current: -2.45

During the past 13 years, the highest EV-to-EBIT of Resverlogix was 67.31. The lowest was -26.50. And the median was 0.00.

RVXCF's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 9.9 vs RVXCF: -2.45

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Resverlogix's Enterprise Value for the quarter that ended in Sep. 2024 was $19.20 Mil. Resverlogix's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-8.50 Mil. Resverlogix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -44.26%.


Resverlogix EV-to-EBIT Historical Data

The historical data trend for Resverlogix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix EV-to-EBIT Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.68 1.14 -4.32 -17.26 -1.41

Resverlogix Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.86 -1.41 -2.24 -2.30 -2.37

Competitive Comparison of Resverlogix's EV-to-EBIT

For the Biotechnology subindustry, Resverlogix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Resverlogix's EV-to-EBIT falls into.



Resverlogix EV-to-EBIT Calculation

Resverlogix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=20.782/-8.496
=-2.45

Resverlogix's current Enterprise Value is $20.78 Mil.
Resverlogix's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Resverlogix  (OTCPK:RVXCF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Resverlogix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=-8.496/19.19734
=-44.26 %

Resverlogix's Enterprise Value for the quarter that ended in Sep. 2024 was $19.20 Mil.
Resverlogix's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Resverlogix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Resverlogix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix Headlines

From GuruFocus

Resverlogix Corp. - Special Call Transcript

By GuruFocus Research 02-14-2024

Resverlogix Corp Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Resverlogix Reschedules Update Webcast and Conference Call

By GlobeNewswire GlobeNewswire 01-27-2021

Resverlogix Announces Annual and Special Meeting of Shareholders

By GlobeNewswire GlobeNewswire 08-22-2019

Resverlogix Corp. - Special Call Transcript

By GuruFocus Research 02-14-2024

Resverlogix Corp. - Special Call Transcript

By GuruFocus Research 02-14-2024

Resverlogix Corp to Provide Corporate Update Transcript

By GuruFocus Research 02-14-2024

Resverlogix Provides Update Regarding Extension of its Filing Calendar

By GlobeNewswire GlobeNewswire 09-12-2020

Resverlogix Announces Withdrawal of Public Offering of Units

By GlobeNewswire GlobeNewswire 06-09-2018